February 27, 2015 2:59 AM ET


Company Overview of Epimmune Inc.

Company Overview

As of August 16, 2005, Epimmune Inc. was acquired by IDM Pharma, Inc. It is a reverse merger transaction. Immuno-Designed Molecules SA. Epimmune, Inc., is a biopharmaceutical company, engages in the development of therapeutic and preventative vaccine solutions, services, and other products. The company is developing therapeutic vaccine drug candidates for the treatment of diseases, such as HIV; hepatitis C; Papilloma virus and hepatitis B virus; and tumors, which include breast, colon, lung, and prostate. It is also developing prophylactic vaccine drug candidates for treating disease, such as HIV, Malaxia, and Hepatitis C. In addition, the company is developing Ex Vivo Immunotherapy for vari...

5820 Nancy Ridge Drive

San Diego, CA 92121

United States

37 Employees





Key Executives for Epimmune Inc.

Epimmune Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Caliber Therapeutics, Inc. United States
Essentially Pure Ingredients United States
bioCSL Inc. United States
Boiron-Borneman, Inc. United States
PharmaNutrients, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Epimmune Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.